Sotera Health Co — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Q3 2026: net revenues $324.9M (+4.4% YoY), net income $58.4M ($0.20/share), Adjusted EBITDA $170.7M (+3.9%). Company reaffirmed full-year 2026 guidance: revenue $1.233B–$1.250B (5.25%–6.75% constant currency growth), Adjusted EBITDA $632M–$641M (5.75%–7.25% growth). Three segments: Sterigenics grew 8.2% (cc), Nelson Labs 9.2% (cc), Nordion declined 11.5% (cc) due to Co-60 harvest timing. Net Leverage improved to 2.9x from 3.2x YE 2025; Moody's upgraded credit rating in early October. No material M&A, restructuring, or strategic shift disclosed.
Why this rating
Solid but modest organic growth (~5–6% cc), within prior guidance. No surprises, no strategic pivots, no major headwinds. Deleveraging and credit upgrade are positive but incremental. Routine quarterly print.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.